• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    5/8/25 4:11:40 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTKB alert in real time by email
    8-K
    false 0001831915 0001831915 2025-05-08 2025-05-08
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):

    May 8, 2025

     

     

    Cytek Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40632   47-2547526

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    47215 Lakeview Boulevard

    Fremont, California

      94538
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (877) 922-9835

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $0.001 per share   CTKB   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.02

    Results of Operations and Financial Condition.

    On May 8, 2025, Cytek Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. The press release is being furnished as Exhibit 99.1.

    The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    Number

      

    Description of Exhibit

    99.1    Press release dated May 8, 2025
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Cytek Biosciences, Inc.
    Date: May 8, 2025     By:  

    /s/ Wenbin Jiang

         

    Wenbin Jiang, Ph.D.

    President and Chief Executive Officer

    Get the next $CTKB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTKB

    DatePrice TargetRatingAnalyst
    5/9/2025$4.00Buy → Hold
    TD Cowen
    1/31/2025$7.00 → $4.50Buy → Sell
    Goldman
    12/14/2023$9.00Overweight
    Stephens
    7/19/2023Mkt Perform
    Raymond James
    2/15/2022$27.00 → $18.00Equal-Weight
    Morgan Stanley
    1/6/2022$20.00Overweight
    Piper Sandler
    10/15/2021Outperform
    Cowen
    8/17/2021Outperform
    Cowen
    More analyst ratings

    $CTKB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Chin Richard

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:31:59 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Chin Richard

      3 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:27:18 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Neff Deborah J

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:25:14 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

      FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora E

      5/29/25 5:00:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference

      FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. Cytek management is scheduled to participate in a fireside chat on Wednesday, June 11th at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next

      5/28/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    SEC Filings

    See more
    • SEC Form 8-K filed by Cytek Biosciences Inc.

      8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

      6/24/25 4:05:58 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Cytek Biosciences Inc.

      SD - Cytek Biosciences, Inc. (0001831915) (Filer)

      5/30/25 4:00:54 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.

      SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      5/15/25 2:07:36 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mccombe William D. bought $97,300 worth of shares (35,000 units at $2.78), increasing direct ownership by 169% to 55,746 units (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/3/25 5:39:17 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Leadership Updates

    Live Leadership Updates

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Cytek Announces Resignation of Chief Operating Officer Chris Williams

      FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef

      9/12/24 3:20:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek® Biosciences Names William McCombe Chief Financial Officer

      Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-

      3/19/24 8:00:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Financials

    Live finance-specific insights

    See more
    • Cytek Biosciences Reports First Quarter 2025 Financial Results

      FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access low-cost manufacturing, increa

      5/8/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

      FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

      4/24/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

      FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9% increases, respectively, over the full year 2023Expanded total Cytek installed base to 3,034 instruments, with 667 total instruments placed during the full year 2024 Net loss in the year ended December 31, 2024 was $6.0 million compared to net loss of $12.1 million in th

      2/27/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 4:35:51 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 1:42:15 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      2/22/24 7:07:27 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CTKB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cytek Biosciences downgraded by TD Cowen with a new price target

      TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

      5/9/25 8:41:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences downgraded by Goldman with a new price target

      Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously

      1/31/25 6:59:30 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Stephens initiated coverage on Cytek Biosciences with a new price target

      Stephens initiated coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $9.00

      12/14/23 6:55:41 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials